Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionKymera Therapeutics Inc. Common Stock (KYMR)
Fair value
Not available
ACCE price target
$100
Rating
Not rated
Horizon
12 months
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Price used: $111 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
51
out of 100
Analysts
92% buy
24 covering
1-year return
+91.8%
Dividend yield
0.00%
Kymera Therapeutics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Kymera Therapeutics develops small-molecule degraders, drugs that tag disease-causing proteins for destruction by the cell's own machinery, and its lead programs target immunology and inflammation through its IRF5 and STAT6 degrader platform. The moat is the platform itself: a set of proprietary degrader chemistry and partnerships, including its collaboration with Sanofi, that brings in upfront and milestone payments before any drug is approved. Those collaboration receipts explain the 466% revenue growth in the data, while gross margin of -258% and operating margin of -116% show the business is still spending well ahead of what it earns, so the story rests on clinical readouts and partner milestones landing on schedule. The stock sits at an 8.9 billion dollar market cap with no earnings to price against, so valuation depends entirely on how the market weights pipeline progress. A score of 51 out of 100 and no index membership suggest the quantitative profile is middling, which makes the clinical calendar the thing to examine before anything else.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
high
Heavy cash burn
Free cash flow is -$234.3M and operating margin is -116.3%. Net margin of -285.3% means the company is losing far more than it books in revenue, so funding depends on its capital position.
moderate
Elevated short interest
Short interest sits at 15.3% of float, a meaningful bet against the stock that can amplify moves in either direction.
moderate
Insider selling without buys
Insiders sold $19.72M across the last 10 disclosed transactions and bought nothing, a one-directional pattern worth noting.
moderate
Price above ACCE target
The stock trades at $110.76, 10.8% above the ACCE price target of $100.00, leaving little margin for error on our own estimate.
AI research notes
AI-assisted·How I use AIWritten Oct 20, 2026 · figures from 2026-10-20 · prices to Oct 23, 2026
Why it could do well
Eleven of the 24 analysts covering the stock rate it Buy or Strong Buy, with 92% of 24 analysts at Buy or Strong Buy.
Analysts' mean price target sits 28.9% above the current share price, implying real upside if their view holds.
The company beat its latest earnings estimate, reporting a loss of $0.62 per share against $0.64 expected.
Why it could disappoint
Free cash flow over the last twelve months was negative at -$234M, so the business is consuming cash rather than generating it.
Net margin of -285.3% means the company keeps very little of its revenue, and losses are large relative to sales.
The share count grew 12.5% in the last fiscal year, diluting existing shareholders' stake in the company.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 3, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where KYMR's valuation models land
Price
$110.76
Model fair valueConfidence: low
about $81.23
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores